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A B S T R A C T
Teicoplanin dosage recommendations for specific infections have been modified in recent years.
However, there was no significant increase in the proportion of pre-dose concentrations > 20 mg ⁄L
between 1994 and 1998 in samples sent for teicoplanin assay at the Regional Antimicrobial Reference
Laboratory, Bristol, UK. A questionnaire on the use of teicoplanin and therapeutic drug monitoring
(TDM) was sent to all UK National External Quality Assurance Scheme antibiotic assay users.
Teicoplanin was widely used in the UK, although vancomycin was more popular as a choice of
glycopeptide. Fewer than 25% recommended teicoplanin TDM during routine use, the main reasons
being perceived lack of toxicity and lack of evidence for the use of teicoplanin TDM. Pre-dose
concentrations < 20 mg ⁄L were considered appropriate for treatment of bacteraemia caused by
methicillin-resistant Staphylococcus aureus by 53% of those responding. Data sheet advice was relied
upon more than TDM as an indication of therapeutic dosing. Microbiologists who mainly used
vancomycin tended to perform more TDM and seek higher serum concentrations when using
teicoplanin than those who preferentially used teicoplanin.
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I N T R O D U C T I O N
Knowledge of the relationship between serum
concentrations of teicoplanin and its therapeutic
effect has accumulated since its introduction to
the UK market in 1991. The UK teicoplanin data
sheet recommends that, for severe infection, pre-
dose concentrations > 10 mg ⁄L should be main-
tained (Aventis Pharma Ltd, West Malling, UK).
The potential significance of minimum post-dose
concentrations has been raised in a few studies
[1,2], but these are not recommended in the data
sheet. Recent studies and meta-analyses have
indicated that doses higher than those recom-
mended in the data sheet may be needed
to achieve pre-dose concentrations > 20 mg ⁄L
for effective treatment of septic arthritis,
Staphylococcus aureus endocarditis and possibly
other deep-seated staphylococcal infections [3–6].
For most UK hospitals, teicoplanin therapeutic
drug monitoring (TDM) entails reference labora-
tory referral, as only a few centres perform in-
house assays for this antibiotic. Taking into
account the relative lack of toxicity of teicoplanin
at standard dosage, there is little indication to
measure serum concentrations in non-severe
infection, with the exception of a few particular
patient groups, e.g., burns patients or intravenous
drug abusers [7,8]. Hence teicoplanin TDM can be
restricted, in most cases, to the management of
serious infections when it is important to ensure
adequate dosing.
The Regional Antimicrobial Reference Labor-
atory at Southmead Hospital (Bristol, UK) first
offered an antibiotic assay service for teicoplanin
in 1993. In the first year, 473 samples were
analysed by fluorescent polarisation immunoas-
say, increasing to 2021 samples in 1999. It might
be expected that published reports over recent
years recommending higher dosages and higher
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serum concentrations would be reflected in the
values of serum concentrations assayed since the
service was introduced. A retrospective study of
serum samples sent to this Antibiotic Reference
Laboratory for teicoplanin assay was carried out
in 1999 to determine whether the changing
recommendations were reflected in the values
of serum concentrations [9]. Surprisingly, over
the 4-year period 1994–98, there was only a
minor increase in the mean value of pre-dose
concentrations analysed from 14.5 mg ⁄L to
16.9 mg ⁄L (p < 0.05), with 23% of all initial pre-
dose teicoplanin concentrations determined in
1994 being ‡ 20 mg ⁄L, compared to 27% in 1998.
The reason for the lack of marked increase in
concentrations and the low proportion of pre-
dose concentrations that were > 20 mg ⁄L was not
clear. In order to answer this question, the
current use of teicoplanin in the UK was
investigated with regard to both dosage and
TDM.
M A T E R I A L S A N D M E T H O D S
A questionnaire, for completion by the consultant medical
microbiologist, was sent in 1999 to all 241 medical microbiology
hospital departments participating in the UK National External
Quality Assurance Scheme for antibiotic assays. Information
was collected on the use of teicoplanin, the preferred glyco-
peptide at each hospital (teicoplanin or vancomycin), and the
reasons for preference. Further questions on dosing, use of
assays, expected concentrations in given clinical circumstances
and source of dosing advice were specific to teicoplanin. Simple
statistical methods (chi-square test) were employed to deter-
mine any correlation between the preferred choice of glyco-
peptide and the selected dosage or use of TDM for teicoplanin.
R E S U L T S
Completed anonymised questionnaires were
returned from 149 of the 241 centres. Responses
from two microbiologists who had only received
part of the questionnaire are included as far as
possible.
Use of teicoplanin
Microbiologists from 139 (93%) hospitals repor-
ted the use of teicoplanin. Nine (6.4%) did not use
teicoplanin at all, for the following reasons (from
a checklist of four): familiarity with vancomycin
(n ¼ 6), cost (n ¼ 5), efficacy concerns (n ¼ 5),
and difficulty with assay (n ¼ 2). These were
excluded completely from further analysis.
Of the 139 microbiologists using teicoplanin,
54 (39%) considered it their first-choice glycopep-
tide, 80 (57%) preferentially used vancomycin,
four (3%) used both equally, and one gave no
answer. Those preferring teicoplanin were asked
to list their reasons (in their own words). The
commonest responses given were ‘no need to
measure levels’ (n ¼ 34; 63%), ‘less toxic or non-
toxic compared to vancomycin’ (n ¼ 29; 54%),
and ‘ease of administration’ (n ¼ 26; 48%). Those
who replied that vancomycin was the first-choice
glycopeptide indicated their reasons (again using
a checklist of up to four suggestions) as being
‘cost concerns’ (n ¼ 58; 73%), ‘familiarity with
vancomycin’ (n ¼ 49; 61%), ‘easier to assay’
(n ¼ 37; 46%), and ‘teicoplanin efficacy concerns’
(n ¼ 40; 50%).
The group preferring vancomycin was then
asked to list the clinical circumstances in which
teicoplanin rather than vancomycin would be
recommended; ‘outpatient or community use’
was the most popular indication, cited by
47 (59%) of all those responding. Other indica-
tions included ‘poor renal function’ (n ¼ 30; 38%),
‘vancomycin allergy or side effects’ (n ¼ 24; 30%),
‘poor or no intravenous access’ (n ¼ 8; 10%), ‘use
with other nephrotoxic drugs’ (n ¼ 8; 10%), and
‘prophylaxis’ (n ¼ 6; 8%). Other reasons given
were: ‘haematology or oncology use’; ‘for entero-
cocci or streptococci’; ‘vancomycin resistance’;
‘paediatrics’; ‘elderly’; ‘prolonged therapy’; ‘line
infection’; and ‘if no central line access’ (each
cited in fewer than six responses).
Dose recommended to treat an adult with
methicillin-resistant Staphylococcus aureus
(MRSA) soft tissue infection
It was expected that the description of ‘an
average-sized adult male’ would be read as a
patient of c. 70 kg body weight as represented in
the standard UK data sheet advice, i.e., ‘Adult
and elderly patients with normal renal function’.
In response, 36 different dosage regimens were
suggested for the management of soft tissue
infection. Some answers included a loading dose
regimen, usually one additional dose in the first
24 h. As this was not specifically asked for, it
cannot be assumed that those who did not
mention loading would not use it, so this has
not been included in the analysis of responses.
Maintenance doses varied widely from 200 mg
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once-daily to ‡ 800 mg once-daily. In a few
responses, the dose was given as dose ⁄ body
weight, with the largest recommended dose being
‘6–10 mg ⁄kg once-daily’. For ease of interpret-
ation, maintenance doses (or the minimum dos-
age in a given range) were grouped as < 400 mg
once-daily, 400 mg once-daily, and > 400 mg
once-daily. The highest doses were recommended
by centres that preferentially used vancomycin
(Fig. 1).
Six responses to this question included mention
of TDM being used to guide dosing. Five
responses were qualified with the initial state-
ment that teicoplanin would not usually be the
antibiotic of choice in this scenario. Other res-
ponses, given without a dose recommendation,
were: ‘only vancomycin would be used in this
scenario’ (n ¼ 1); ‘the data sheet would be used to
select an appropriate dose’ (n ¼ 2); ‘the pharmacy
would give dosing advice’ (n ¼ 1); and ‘not
applicable to a children’s hospital’ (n ¼ 2). One
microbiologist replied that there was ‘‘no MRSA
in the hospital’’.
Use of TDM
TDM would be recommended by 30 (22%) of the
respondents when using teicoplanin. Of these,
five were centres that used teicoplanin frequently
as the first-choice glycopeptide, 23 were centres
where vancomycin was the preferred glycopep-
tide, and two were centres that used both equally.
In 99 (71%) centres, teicoplanin TDM was not
recommended routinely; however, 47 of these
responses were further qualified by a statement
that TDM might be used occasionally in defined
circumstances such as renal failure or in the
treatment of endocarditis. Other responses were
marked ‘not applicable’ or left blank.
The commonest reasons, when stated, for not
recommending the use of teicoplanin TDM were:
‘toxicity not related to levels’ (n ¼ 24; 24%); ‘not
convinced levels useful or no data to support their
use’ (n ¼ 21; 21%); and ‘no assay on site or
nearby’ (n ¼ 9; 9%). Other reasons given inclu-
ded: ‘results not timely’ (n ¼ 3); ‘wide therapeutic
range’ (n ¼ 2); ‘peak level occasionally useful’
(n ¼ 1); ‘cost’ (n ¼ 1); ‘don’t use teicoplanin
monotherapy’ (n ¼ 1); ‘if seriously ill would use
vancomycin’ (n ¼ 1); ‘if need assays would
use vancomycin’ (n ¼ 1); and ‘concentrations
achieved by standard dosage should exceed
MIC of organism’ (n ¼ 1).
All those recommending TDM, whether rou-
tinely or occasionally (n ¼ 77), reported assay of
pre-dose serum samples. In addition, almost half
would also assay post-dose concentrations, but
none reported use of ‘random’ samples. On-site
teicoplanin TDM was performed at 11 (13%)
of the centres that responded. Other centres
reported using assay services at Southmead Hos-
pital, Bristol (n ¼ 54), University College Hospi-
tal, London (n ¼ 7), Mater Misericordae Hospital,
Dublin (n ¼ 5), Newcastle Public Health Labor-
atory (n ¼ 1), Belfast Royal Victoria Hospital
(n ¼ 1), and Southern General Hospital, Glasgow
(n ¼ 1).
Desirable serum concentrations
Respondents were asked to indicate the tei-
coplanin serum concentrations that they consid-
ered desirable for the treatment of MRSA
cellulitis, osteomyelitis, and bacteraemia. Almost
all responses gave recommended pre-dose rather
than post-dose concentrations. Two responses
indicated only peak concentrations for each case
(of 25–60 and 20–30 mg ⁄L, respectively). No pre-
dose or post-dose concentration > 60 mg ⁄L was
recommended in any response. Responses were
grouped according to the minimum acceptable
concentration indicated where a range of accept-
able concentrations was given, and further
subgrouped according to the glycopeptide of
choice. Responses from two centres with no
glycopeptide preference were excluded. Accept-
able pre-dose concentrations for MRSA cellulitis
ranged from < 10 mg ⁄L to > 20 mg ⁄L (Fig. 2).
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Fig. 1. Recommended daily teicoplanin dosage (mg ⁄ kg)
for MRSA cellulitis. T users, V users: microbiologists using,
respectively, teicoplanin or vancomycin as their first-
choice glycopeptide, once-daily.
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Peak concentration recommendations were also
included in five responses. As with the responses
for MRSA osteomyelitis and MRSA bacteraemia,
there was a general trend towards a requirement
for higher concentrations by those preferring to
use vancomycin. However, on direct comparison
of pre-dose concentrations of < 20 mg ⁄L and
‡ 20 mg ⁄L, this trend did not reach statistical
significance (p > 0.05).
Desirable pre-dose concentrations suggested
for MRSA osteomyelitis were higher than for cel-
lulitis (Fig. 3). A pre-dose concentration ‡ 20 mg ⁄L
was considered desirable by 54% of respond-
ents. Peak concentrations in addition to troughs
were indicated in six responses, and two other
responses only stated peak concentrations (20–
30 mg ⁄L and 25–60 mg ⁄L, respectively). One
centre stated that it would not check concentra-
tions in this situation, and other responses were
unclear or marked not applicable.
In the third case scenario, recommended pre-
dose concentrations for MRSA bacteraemia were
similar to those for osteomyelitis (Fig. 4), with
no microbiologist accepting a concentration
< 10 mg ⁄L (n ¼ 57). Pre-dose concentrations
< 20 mg ⁄L were accepted by 25 (44%) of 57 res-
pondents, but two of these stipulated that, for
endocarditis, the pre-dose concentration should
be > 20 mg ⁄L. Thirty (53%) responses stated that
pre-dose concentrations should be > 20 mg ⁄L,
including four which stated that their response
was specific for the treatment of endocarditis.
Two microbiologists expected a minimum pre-
dose concentration of 30 mg ⁄L. A further two
responses indicated only post-dose concentra-
tions, and nine included post-dose concentrations
with the pre-dose recommendations. One centre
stated that it would not use TDM in this
circumstance, and four responses were unclear.
Effect of assay results on dosing regimen
If the teicoplanin assay demonstrated a concen-
tration lower than anticipated, most (63; 81%)
respondents stated that they would increase the
dose, while five (6%) would maintain the same
dose and re-assay. The proportions of each
response were equally divided between the group
preferring to use teicoplanin and the group
preferring to use vancomycin. Six indicated that
both options would be employed, and seven
responded with ‘not applicable.’ ‘Other’ respon-
ses given included: ‘discuss with reference
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Fig. 3. Desired pre-dose teicoplanin concentrations for
MRSA osteomyelitis according to preferred glycopeptide.
T users, V users: microbiologists using, respectively,
teicoplanin or vancomycin as their first-choice glycopep-
tide.
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Fig. 4. Desired pre-dose teicoplanin concentrations for
MRSA bacteraemia according to preferred glycopeptide.
T users, V users: microbiologists using, respectively,
teicoplanin or vancomycin as their first-choice glycopep-
tide.
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Fig. 2. Desired pre-dose teicoplanin concentrations for
MRSA cellulitis according to preferred glycopeptide. T
users, V users: microbiologists using, respectively, teicopl-
anin or vancomycin as their first-choice glycopeptide.
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laboratory’ (n ¼ 1); ‘change antibiotic’ (n ¼ 2);
and ‘continue with twice-daily dose until levels
acceptable’ (n ¼ 2).
Source of guidance for teicoplanin dosing
advice
The final question concerned the source that was
relied on for an indication of therapeutic dosing
for teicoplanin: the British National Formulary
(BNF) or data sheet; assay results; or ‘other
guidelines’. Overall, nearly half (49%) of all
those responding (n ¼ 111) used BNF dosing
recommendations as the main indication of
therapeutic dosing, 29 (26%) relied more on
assay results, and 12 (11%) said that they would
use both. Other responses included: ‘expert
advice’ (n ¼ 4); ‘literature ⁄publications’ (n ¼ 7);
‘own hospital recommendations’ (n ¼ 4); and
‘clinical response’ (n ¼ 3).
On comparison of the responses by first choice
of glycopeptide, of those preferentially using
teicoplanin (n ¼ 40), 29 (73%) reported relying
on BNF recommendations, while six (15%) relied
more on assay results. In comparison, of those
using mostly vancomycin (n ¼ 60), 24 (40%)
relied mainly on BNF recommendations when
using teicoplanin, and 21 (35%) relied more on
assay results (p < 0.01).
D I S C U S S I O N
The present study reports on teicoplanin TDM
practice in 149 UK hospitals, all of which parti-
cipate in the UK National External Quality Assur-
ance Scheme for antibiotic assays. It cannot be
assumed that this represents the practice in all UK
hospitals; microbiologists not using teicoplanin
may have been less likely to return the question-
naire. However, the results may reflect overall
trends.
Teicoplanin was widely used, but vancomycin
was the first-choice glycopeptide in most respond-
ing hospitals. A small proportion of microbiolo-
gists do not recommend the use of teicoplanin at
all. Cost concerns, followed by familiarity with
vancomycin, appear to be the main reasons for
vancomycin preference, while half of the vanco-
mycin users indicated that they had concerns
with the efficacy of teicoplanin. In contrast,
perceived lack of need for assays and the lower
toxicity of teicoplanin were most frequently cited
as reasons by those favouring teicoplanin over
vancomycin.
Familiarity with a particular drug may not
always be a valid reason for selecting it, but there
is certainly some evidence to demonstrate the
superiority of vancomycin over teicoplanin
monotherapy in some infections, e.g., severe
staphylococcal infections [2,10–12]. The initial
acquisition costs of teicoplanin are higher than
those of vancomycin, although this may be offset
in part by the nursing time required for admin-
istration of the vancomycin infusion and the cost
of disposable equipment and assays. It has been
suggested that the cost of using teicoplanin over
longer courses of therapy is much closer to that of
vancomycin [13], or even less when considering
its use in the outpatient setting. This is now even
more likely, as the cost of teicoplanin has recently
fallen in the UK. The prolonged half-life of
teicoplanin enables once-daily dosing, and some
centres have reported alternate-day dosing for
outpatient and home parenteral antibiotic therapy
patients [14–17], securing its role in outpatient
intravenous therapy as indicated by over half of
the vancomycin users.
The nephrotoxicity of vancomycin is contro-
versial. Certainly, it demonstrates greater neph-
rotoxic potential when combined with, for
example, aminoglycosides than does teicoplanin
[18–20]. Whether it is more nephrotoxic than
teicoplanin when given as monotherapy is ques-
tionable [21,22]; however, ‘renal failure or impair-
ment’ was cited as a reason for recommending
teicoplanin by nearly 40% of those who would
usually use vancomycin.
An important pharmacodynamic factor in
effective treatment with teicoplanin has been
shown to be the time for which the serum
concentration remains above the MIC (T > MIC)
[5]. Infrequent dosing is therefore feasible as long
as serum concentrations do not fall below the MIC
of the isolate (MIC < 4 mg ⁄L) [23]. A relationship
between outcome and maximum and minimum
serum concentrations was found in one review of
teicoplanin trials, but there was no direct corre-
lation between dose and outcome [5]. There is no
evidence in vitro of concentration-dependent kill-
ing when large doses are used [24,25]. Ideally,
TDM would incorporate all patient, pharmacoki-
netic and pharmacodynamic factors to reach the
optimum dosage regimen for each patient
infected by a specific organism. Using standard
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target concentrations for all patients is therefore a
simplistic method of optimising dose regimens,
but one that is much more accessible and man-
ageable than, for example, applying population
pharmacodynamic or pharmacokinetic modelling
data to each patient.
The perceived lack of need for teicoplanin TDM
in centres that use teicoplanin most frequently is
interesting. For mild-to-moderate infection, there
is little evidence to support its use unless abnor-
mal renal clearance is anticipated, e.g., in intra-
venous drug abusers or renally impaired patients
[8,26]. In severe infection, including joint infection
and endocarditis, the relationship between out-
come and pre-dose teicoplanin concentration is
well-documented [3–5,27]. It has been shown that,
for staphylococcal endocarditis and septic arthri-
tis, a pre-dose concentration > 20 mg ⁄L is associ-
ated with improved outcome [28,29]. The fact that
two-thirds of those who mainly use teicoplanin
state that the lack of need to perform TDM is a
major advantage is therefore surprising. Consid-
erable inter-individual variability in the serum
concentrations of patients given the same doses of
teicoplanin has been demonstrated [12,30]. Fur-
thermore, at the time of the survey, the teicoplanin
assay service was provided free of charge, so the
cost implications were minimal. Teicoplanin data
sheet recommendations may be considered some-
what conservative with respect to treatment of
severe infection. As discussed, there is evidence to
indicate that pre-dose concentrations > 20 mg ⁄L
are required for efficacy in some infective condi-
tions, and some authors have even recommended
concentrations > 30 mg ⁄L [3].
Maintenance doses of 200–400 mg may be
adequate for soft tissue infection, but higher
doses are needed to attain pre-dose concentra-
tions > 20 mg ⁄L [31]. The wide range of dose
recommendations for the treatment of MRSA
cellulitis reported in question 3 suggests that
there is no overall consensus about teicoplanin
dosage for mild-to-moderate infection. However,
this is also likely to be true for the management
of mild infection with any other antibiotic. Those
using vancomycin much more frequently than
teicoplanin recommended the highest doses of
teicoplanin, i.e., > 400 mg. This could be attrib-
uted to unfamiliarity with the dosing schedules,
or with teicoplanin itself, but is more likely to
reflect the ‘efficacy concerns’ indicated by over
half of those preferring to use vancomycin. It was
also interesting to note that, of all respondents
who stated that they would recommend teicopla-
nin TDM, the majority were those who preferen-
tially used more vancomycin. These vancomycin
users also recommended higher mean pre-dose
teicoplanin concentrations for each of the three
clinical scenarios. Again, this may reflect personal
concerns with efficacy at standard dosage, but
could also indicate a greater familiarity with more
recent publications of teicoplanin dosage recom-
mendations. It may also explain why the cost of
using teicoplanin (at higher doses) is a concern for
many vancomycin users.
As anticipated, increases in the ranges and
mean pre-dose concentrations suggested for
MRSA cellulitis, osteomyelitis and bacteraemia,
respectively, were observed. In many cases, the
responses appeared to reflect either BNF or data
sheet advice, or more recent publications (e.g.,
‘‡ 10 mg ⁄L’ or ‘> 20 mg ⁄L’). In some responses, it
was not clear whether acceptance of pre-dose
concentrations < 10 mg ⁄L or, as specifically stated
in two responses, ‘> 18 mg ⁄L’ or ‘> 22 mg ⁄L’ was
based on personal experience or some other
evidence. Within the limits of reproducibility of
the fluorescent polarisation immunoassay (10%
error margin), a sample containing 20 mg ⁄L
teicoplanin might be reported as having a con-
centration between 18.0 mg ⁄L and 22.0 mg ⁄L.
It is therefore unlikely that aiming for a minimum
pre-dose concentration of specifically 18 mg ⁄L or
22 mg ⁄L on TDM will effect a significant differ-
ence in outcome when compared with 20 mg ⁄L.
A concentration of < 10 mg ⁄L may be quite
appropriate for mild infection, but it is question-
able whether assays must be performed at all in
these cases. The minimum pre-dose concentra-
tions suggested for S. aureus bacteraemia varied
from ‡ 10 mg ⁄L to > 30 mg ⁄L. Four responses
stated that concentrations > 20 mg ⁄L were requi-
red for the specific treatment of endocarditis, and
there is evidence to show that concentrations
maintained above 20 mg ⁄L improve outcome for
staphylococcal endocarditis. Teicoplanin is not
recommended in the current UK guidelines for
the treatment of staphylococcal endocarditis [32].
However, endocarditis may complicate up to
10–60% cases of S. aureus bacteraemia [33], so
there is logic in maintaining concentrations
> 20 mg ⁄L for all cases of S. aureus bacteraemia,
particularly if community acquired, until endo-
carditis has been excluded [5].
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When assay results indicate subtherapeutic
concentrations, the common response is to
increase the dose. Following a once-daily dosing
regimen of 3 mg ⁄ kg (without loading), a teicopl-
anin steady-state concentration was reached by
day 10 in healthy volunteers [34]. However, if,
following a loading dose, the pre-dose concentra-
tion after 3–5 days is still subtherapeutic, it is
appropriate to increase the dose. Prolonging the
loading period, as suggested in two responses, to
reach steady state rapidly has been described [35],
and may be a useful approach for severe infection
when therapeutic levels must be reached imme-
diately.
Finally, it was considered that the source of
dosing advice might explain absence of a signi-
ficant increase in serum concentrations over
recent years. Overall, nearly half of those
responding reported relying mainly on the BNF
or data sheet as their indication of therapeutic
dosing, i.e., using a maximum daily dose of
400 mg for adults weighing < 85 kg. Fewer than
one-third reported relying mainly on results of
serum assay to guide therapeutic dosing. A
significantly higher percentage of those using
teicoplanin in preference to vancomycin rely
more on the BNF as their main dosing guide.
Does this mean that those familiar with the use of
teicoplanin feel comfortable with the efficacy
observed using standard dosing and see no need
to increase dosage? Other possible reasons for this
difference have already been discussed. As this
was an anonymous survey, it is not possible to
comment on the individual hospitals represented
in each response. It would be interesting to know
whether those preferentially using teicoplanin,
and particularly those using the more conven-
tional doses, represent a different size of hospital
and patient mix compared to those using higher
doses (e.g., District General Hospitals vs. tertiary
referral centres).
In conclusion, there has been no marked
increase in the mean pre-dose teicoplanin con-
centrations assayed at the Regional Antibiotic
Reference Laboratory at Southmead Hospital in
recent years. Teicoplanin was widely used in UK
hospitals, but was not the most popular ‘first-
choice’ glycopeptide in those surveyed. There
was a tendency towards lower mean dosage,
less frequent assay and requirement for lower
pre-dose concentrations by those who considered
it their first-choice glycopeptide. Whether this
was caused by lack of awareness, or acceptance
of more recent evidence, or simply familiarity
and acceptance of efficacy with teicoplanin at the
doses used, was not known. The data sheet was
still relied on more than assay results as an
indicator of therapeutic dosing, but the propor-
tion was significantly higher in the group that
used teicoplanin most frequently. If the data
sheet was updated to reflect the findings of
recent studies, it would be interesting to observe
what changes in the use of teicoplanin might
follow. For example, would the teicoplanin users
currently following data sheet guidance continue
to use the dose they have experience of, increase
the dose to observe new data sheet recommen-
dations, or switch to using more vancomycin to
avoid escalating drug acquisition costs, and start
using TDM for vancomycin instead?
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